The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Open accessAbstract
OBJECTIVE: Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression. METHODS: Clinical follow-up was obtained 20 ± 3 months after [¹¹C]Pittsburgh compound B (PiB)-positron emission tomography in 206 subjects: 35 with dementia of the Alzheimer type (DAT), 65 with mild cognitive impairment (MCI), and 106 age-matched healthy controls (HCs). A second PiB scan was obtained at follow-up in 185 subjects and a third scan after 3 years in 57. RESULTS: At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention. At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively). Increases were associated with the number of apolipoprotein E ε4 alleles. There was a weak correlation between PiB increases and decline in cognition when all groups were combined. Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of the high PiB HCs, 16% developed MCI or DAT by 20 months and 25% by 3 years. One low PiB HC developed MCI. INTERPRETATION: Aβ deposition increases slowly from cognitive normality to moderate severity DAT. Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years. However, cognitive decline is only weakly related to change in Aβ burden, suggesting that downstream factors have a more direct effect on symptom progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have shown that CU individuals with abnormal amyloid biomarkers have more rapid progression of atrophy, hypometabolism, and clinical/cognitive decline than individuals without biomarker evidence of Aβ deposition [13,33,80,93–99]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a study characterizing sporadic AD, for instance, Villemagne et al. used Pittsburgh compound B (PiB) positron emission tomography (PET) to show that 31% of healthy control subjects had high PiB retention indicating Aß deposition and of these, 25% developed mild cognitive impairment or AD by 3 years (Villemagne et al., 2011).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Villemagne et al., 2011
In the citing paper
“Previous longitudinal studies have either failed to detect an early increase in regional Aβ deposition16 or identified a rather large early stage Aβ region including the posterior temporal, inferior parietal, posterior cingulate, precuneus, and occipital areas4.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Design and construction of a realistic digital brain phantom
Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.712135 · Cited by 1,825
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 836
La neuroimagen molecular en las demencias degenerativas
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2013.06.012 · Cited by 9
A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET/CT
Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Martínez‐Rodríguez, I., Martínez‐Amador, N., Sánchez-Salmón, A., la Fuente-Gómez, F. D., Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., & Banzo, I. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001004 · Cited by 8
Brown, E. E., Rashidi‐Ranjbar, N., Caravaggio, F., Gerretsen, P., Pollock, B. G., Mulsant, B. H., Rajji, T. K., Fischer, C. E., Flint, A. J., Mah, L., et al. (2019) · Journal of Neuroimaging · doi:10.1111/jon.12646 · Cited by 8
Genome-Wide Association Study Identifies SLAMF1 Affecting the Rate of Memory Decline
Chen, S.-D., Initiative, O. B. O. A. D. N., Li, H., Shen, X., Li, J., Xu, W., Huang, Y., Tan, L., Dong, Q., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191214 · Cited by 8
Terrera, G. M., Harrison, J., Ritchie, C. W., & Ritchie, K. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191108 · Cited by 8
B-Tensor: Brain Connectome Tensor Factorization for Alzheimer's Disease
Durusoy, G., Yldrm, Z., Dal, D. Y., Ulaşoğlu-Yıldız, Ç., Kurt, E., Bayr, G., Ozacar, E., Özarslan, E., Demirtaş-Tatlıdede, A., Bılgıç, B., et al. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3023610 · Cited by 8
Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid-β
Gureviciene, I., Gurevicius, K., Mugantseva, E., Kislin, M., Khiroug, L. S., & Tanila, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160453 · Cited by 8
McCluskey, G. E., Yates, P., Villemagne, V. L., Rowe, C., & Szoeke, C. E. I. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9668-5 · Cited by 7
Self-citationNotzon, S., Alferink, J., & Arolt, V. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0193-y · Cited by 10
Kokje, E., Çelik, S., Wahl, H., & von Stutterheim, C. (2021) · European Journal of Ageing · doi:10.1007/s10433-021-00619-5 · Cited by 7
Alzheimer’s Disease and Other Dementias
Brugulat‐Serrat, A., Shaaban, C. E., Emrani, S., & Sundermann, E. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-87228-0_5 · Cited by 7
Advances in gait research related to Alzheimer’s disease
Yan, S., Yun, X., Liu, Q., Hong, Z., Chen, Y., & Zhang, S. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1548283 · Cited by 8
Predicting Symptom Onset in Sporadic Alzheimer’s Disease: “How Long Do I Have?”
Schindler, S. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215722 · Cited by 7
Measuring disease progression in corticobasal syndrome
Huang, N., Hornberger, M., Hodges, J. R., & Burrell, J. R. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7389-5 · Cited by 7
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
Thientunyakit, T., Sethanandha, C., Muangpaisan, W., Chawalparit, O., Arunrungvichian, K., Siriprapa, T., Thongpraparn, T., Chanachai, R., & Gelovani, J. G. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000787 · Cited by 7
Lessons from a Rare Familial Dementia: Amyloid and Beyond
Cantlon, A., Frigerio, C. S., & Walsh, D. M. (2015) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000009 · Cited by 8
Hampstead, B. M., & Brown, G. S. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.007 · Cited by 7
Pham, H., Yin, T., & D’Adamio, L. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263546 · Cited by 6
Ultra-Early Screening of Cognitive Decline Due to Alzheimer’s Pathology
Wei, P. (2023) · Biomedicines · doi:10.3390/biomedicines11051423 · Cited by 7
Ji, S., Kang, J., Han, C., Xu, X., Chen, M., Chen, J., Chhetri, J. K., Pan, J., & Chan, P. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1330193 · Cited by 6
David, J., Quenon, L., Hanseeuw, B. J., Ivanoiu, A., Volfart, A., Koessler, L., & Rossion, B. (2024) · Clinical Neurophysiology · doi:10.1016/j.clinph.2024.12.018 · Cited by 6
Childhood maltreatment confers long-term risk for cognitive impairment: A prospective investigation
Assuras, S., Courtney, K., Maxfield, M., Shagalow, S., Sherer, S., Manly, J. J., & Widom, C. S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100303 · Cited by 6
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 8
LAM Test: A New Cognitive Marker for Early Detection in Preclinical Alzheimer’s Disease
García-Martínez, M., Pozueta‐Cantudo, A., Lage, C., Martínez‐Dubarbie, F., López‐García, S., Fernández‐Matarrubia, M., Corrales‐Pardo, A., Bravo, M., Cavada-Bustamante, N. C., Anuarbe, P., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240067 · Cited by 6
Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer’s disease using ADNI
Elhefnawy, M. E., Patson, N., Mouksassi, S., Pillai, G. C., Shcherbinin, S., Chigutsa, E., & Gueorguieva, I. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09959-y · Cited by 6
Lee, A., Hwang, E., & Hwang, J. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110248 · Cited by 6
Gains and losses on the road to understanding Alzheimer’s disease
Konietzko, U. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14233 · Cited by 6
Genetic and degenerative disorders primarily causing dementia
Masdeu, J. C., & Pascual, B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00026-x · Cited by 6
Amnestic mild cognitive impairment
Butler, C., & Ahmed, S. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.016 · Cited by 6
Clinical Assessment of Amyloid Imaging in Alzheimer's Disease: A Systematic Review of the Literature
Wahlster, P., Niederländer, C., Kriza, C., Schaller, S., & Kolominsky‐Rabas, P. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000351679 · Cited by 8
Positron Emission Tomography in Alzheimer Disease
Schmidt, M. E., Matthews, D. C., Andrews, R. D., & Mosconi, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00005-6 · Cited by 7
The Role of Genetics in Alzheimer's Disease and Parkinson's Disease
Porter, T., Gozt, A., Mastaglia, F. L., & Laws, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch15 · Cited by 6
Impact of APOE ε3 and ε4 genotypes on plasma proteome signatures in Alzheimer's diseasePreprint
Kaur, G., Poljak, A., Masters, C. L., Fowler, C. J., & Sachdev, P. S. (2022) · Research Square · doi:10.1101/2022.01.29.478291 · Cited by 4
Self-citationMapping Alzheimer's disease heterogeneity with molecular imaging biomarkers
Harput, E., Boccalini, C., Mathoux, G., Prior, J. O., Dardel, N. T., Jreige, M., & Garibotto, V. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70163 · Cited by 5
Volloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116036 · Cited by 6
Park, K. H., Choi, S. H., Shim, Y., Youn, Y. C., Yang, D. W., & Kim, S. (2025) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0037 · Cited by 6
van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Cited by 5
Jeong, S. H., Cha, J., Jung, J. H., Yun, M., Sohn, Y. H., Chung, S. J., & Lee, P. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230187 · Cited by 5
López, O. L., Villemagne, V. L., Chang, Y., Cohen, A. D., Klunk, W. E., Mathis, C. A., Pascoal, T. A., Ikonomović, M. D., Rowe, C. C., Doré, V., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207920 · Cited by 5
Self-citationHemminghyth, M. S., Chwiszczuk, L. J., Breitve, M. H., Gísladóttir, B., Grøntvedt, G. R., Nakling, A. E., Rongve, A., Fladby, T., & Kirsebom, B. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.005 · Cited by 8
Mikos, A. E., Piryatinsky, I., Tremont, G. N., & Malloy, P. F. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318266c6c3 · Cited by 5
Imaging cerebral amyloid plaques: clinical perspective
Herholz, K. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70158-8 · Cited by 5
First, M. B., Carter, C., Castellanos, F. X., Dickstein, D. P., Drevets, W. C., Kim, K. L., Pescosolido, M. F., Rausch, S., Seymour, K. E., & Zubieta, J.-K. (2012) · Cited by 5
Alzheimer’s Disease: Clinical Trials and the Amyloid Hypothesis
Cummings, J. L. (2011) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v40n7p304 · Cited by 5
Yeo, J. M., Waddell, B., Khan, Z. H., & Pal, S. (2015) · Cited by 5
Lim, Y. Y., Pase, M. P., Buckley, R. F., Yassi, N., Bransby, L., Fowler, C. J., Laws, S. M., Masters, C. L., & Maruff, P. T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201281 · Cited by 6
Self-citationPET and SPECT Imaging of Neurodegenerative Diseases
Drzezga, A. E., Bischof, G. N., Giehl, K., & van Eimeren, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00085-5 · Cited by 4
Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103321 · Cited by 5
Almkvist, O., Brüggen, K., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201612 · Cited by 4
Gao, F., Shang, S., Chen, C., Dang, L., Gao, L., Wei, S., Wang, J., Huo, K., Deng, M., Wang, J., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.557005 · Cited by 5
The role of amyloid beta 4-42 in the etiology of Alzheimer's disease
Bouter, Y. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4849 · Cited by 5
Rådestig, M. A., Skoog, J., Zetterberg, H., Kern, J., Zettergren, A., Sacuiu, S. F., Wærn, M., Wetterberg, H., Blennow, K., Skoog, I. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200751 · Cited by 5
Park, D. C., & Farrell, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00005-4 · Cited by 4
Clinical trials of promising apoptosis modulating drugs
Sharma, N., Kumari, R. M., Arya, G., Gupta, N., Chandra, R., & Nimesh, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815762-6.00010-x · Cited by 4
Lee, D., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00719-3 · Cited by 6
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Self-citationKim, Y. J. (2017) · Brain & Neurorehabilitation · doi:10.12786/bn.2017.10.e4 · Cited by 5
The Panomics Approach in Neurodegenerative Disorders
Szatmári, B., Balicza, P., Németh, G., & Molnár, M. J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705120038 · Cited by 4
Yeung, L., Hale, C., Last, B. S., Andrews, H., Sloan, R. P., Honig, L. S., Small, S. A., & Brickman, A. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.010 · Cited by 4
Hypochlorous Acid Activating MB‐O to Release Methylene Blue for Photodegrading of Aβ Aggregates
Bao, X., Yao, Y., Xu, Y., Shen, Y., Lv, G., Zhao, D., & Li, C. (2021) · Zeitschrift für anorganische und allgemeine Chemie · doi:10.1002/zaac.202100253 · Cited by 4
Advances in structural and molecular neuroimaging in Alzheimer's disease
Ellis, K. A., Rowe, C. C., Szoeke, C. E. I., Villemagne, V. L., Ames, D. J., Chételat, G., Martins, R. N., Masters, C. L., Fripp, J., Acosta, O., et al. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb02938.x · Cited by 4
Self-citationRisk and resilience: A new perspective on Alzheimer's disease
Teipel, S. J. (2013) · Geriatric Mental Health Care · doi:10.1016/j.gmhc.2013.04.003 · Cited by 6
Analyzing Mild Cognitive Impairment Progression via Multi-view Structural Learning
Wang, L., Thompson, P. M., & Zhu, D. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-20351-1_51 · Cited by 4
Mathoux, G., Harput, E., Peretti, D. E., Boccalini, C., & Garibotto, V. (2026) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001471 · Cited by 3
Wake‐promoting neuromodulators in Alzheimer's disease: Implications for sleep and brain clearance
Pedersen, T. J., Clemens, S. G., Winer, J. R., Sharma, A., Falgàs, N., Lucey, B. P., Gordon, B. A., & Musiek, E. S. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71298 · Cited by 5
Terskov, A. V., Alexander, S., Blokhina, I., Zlatogorskaya, D., Adushkina, V., Anastasiia, S.-G., Kumar, A., Ivan, F., Evsukova, A., & Semyachkina-Glushkovskaya, O. V. (2025) · Frontiers of Optoelectronics · doi:10.1007/s12200-025-00149-3 · Cited by 4
alzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Dementia with Lewy bodies – a clinicopathological update
Bencze, J., Seo, W., Hye, A., Aarsland, D., & Hortobágyi, T. (2019) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2613 · Cited by 4
Campanioni, S., González‐Nóvoa, J. A., Busto, L., Agís‐Balboa, R. C., & Veiga, C. (2023) · Biomedicines · doi:10.3390/biomedicines11020273 · Cited by 3
Duwat, C., Léal, P., Vautheny, A., Aurégan, G., Joséphine, C., Gaillard, M., Hérard, A., Jan, C., Gipchtein, P., Mitja, J., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106116 · Cited by 6
Transforming Neurology and Psychiatry
Taha, A., Alassi, A., GJEDDE, A. H., & Wong, D. F. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.06.002 · Cited by 3
Majkutewicz, I., Kurowska, E., Ruciński, J., Myślińska, D., Grembecka, B., Mantej, J., & Dzik, K. P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04024-8 · Cited by 3
Huang, Y., Cao, C., Dai, S., Deng, H., Su, L., & Zheng, J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae150 · Cited by 4
Alzheimer’s Disease: Epidemiology, Etiology, Risk Factors, and Future Predictions
Jojo, G. M., Johnson, J., Kuppusamy, G., & Karri, V. V. S. R. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_3 · Cited by 3
Lopez, S., Hampel, H. J., Percio, C. D., Noce, G., Lizio, R., Teipel, S. J., Dyrba, M., González‐Escamilla, G., Bakardjian, H., Chiesa, P. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70438 · Cited by 2
Shea, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.039 · Cited by 3
Tracking brain amyloid-β in presymptomatic Alzheimer's disease
Jagust, W. J. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70255-7 · Cited by 3
Biochemical and Radiological Markers of Alzheimer’s Disease Progression
Dziedzic, T., Pera, J., Klimkowicz‐Mrowiec, A., Mroczko, B., & Słowik, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/ifs-150578 · Cited by 3
Cerebral lactate metabolism and memory: Implications for Alzheimer's disease
Harris, R. A. (2017) · Scholarship@Western (Western University) · Cited by 3
The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease
Kurz, A., & Lautenschlager, N. T. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_17 · Cited by 3
Minhas, D. S., Yang, Z., Muschelli, J., Laymon, C. M., Mettenburg, J., Zammit, M. D., Johnson, S. C., Mathis, C. A., Cohen, A. D., Handen, B. L., et al. (2020) · Communications in computer and information science · doi:10.1007/978-3-030-50153-2_28 · Cited by 3
Self-citationPET Imaging of Amyloid and Tau in Alzheimer’s Disease
Okamura, N., & Harada, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_19 · Cited by 3
Glial changes and gene expression in Alzheimer's disease from snRNA-Seq and spatial transcriptomics
Wei, S., Li, C., Li, W. Q., Yuan, F., Kong, J., Su, X., Huang, P., Guo, H., Xu, J., & Sun, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330320 · Cited by 3
Abbate, C., & Gallucci, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374319 · Cited by 2
Xie, K., Ryan, D. P., Schröder, S., Freund, L. J., Bonn, S., Zhou, Y., & Ehninger, D. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03682-2 · Cited by 2
Doroudinia, A., York, B., & Colletti, P. M. (2026) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.271678 · Cited by 2
Brown, C., Cousins, K. A. Q., Korecka, M., McGrew, E., Chen‐Plotkin, A. S., Detre, J. A., McMillan, C. T., Lee, E. B., Das, S. R., Mechanic-Hamilton, D. J., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78194 · Cited by 4
30 years of [11C]methyl triflate
Jewett, E. M., Någren, K., Mock, B. H., & Watkins, G. L. (2023) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2023.110812 · Cited by 3
Predicting cognitive decline in older people by structural and molecular imaging
Teipel, S. J., Tang, Y., & Boccardi, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001172 · Cited by 2
Wybitul, M., Buchmann, A., Langer, N., Höck, C., Treyer, V., & Gietl, A. F. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.03.007 · Cited by 2
Volloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189913 · Cited by 3
Association of immunity-related gene SNPs with Alzheimer’s disease
Bissar‐Tadmouri, N., Kassir, R., Salami, A., & Shamieh, S. E. (2024) · Experimental Biology and Medicine · doi:10.3389/ebm.2024.10303 · Cited by 2
Volloch, V., & Rits‐Volloch, S. (2025) · Genes · doi:10.3390/genes16010046 · Cited by 3
Tian, Q., Dong, Q., Su, Z., Liu, Y., Ma, L., Dong, H., Xu, Y., Ma, Z., Chen, X., & Ma, X. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251315011 · Cited by 2
What to make of equivocal amyloid imaging results
Burrell, J. R., Foxe, D., Leyton, C. E., Piguet, O., & Hodges, J. R. (2020) · Neurocase · doi:10.1080/13554794.2020.1764056 · Cited by 2
What Can We Learn From Regional Vulnerability to amyloid-β Accumulation in Nondemented individuals?
Shinohara, M., & Bu, G. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.20 · Cited by 2
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation
Price, J. C., Mathis, C. A., & Klunk, W. E. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-s2-a31 · Cited by 2
Self-citationAmyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
Leuzy, A., Zimmer, E. R., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Translational Neuroscience · doi:10.2478/s13380-014-0205-y · Cited by 2
Neurocognitive Methods in Higher Cognition
Morrison, R. G., & Knowlton, B. J. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199734689.013.0006 · Cited by 2
Metadata
- Authors
- Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C.
- Affiliations
- Mental Health Research Institute (AU)
- Austin Health (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Australian e-Health Research Centre (AU)
- Edith Cowan University (AU)
- University of Pittsburgh (US)
- National Ageing Research Institute (AU)
- The University of Melbourne (AU)
- Corresponding author
- Villemagne, Victor L.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 69
- Issue
- 1
- Pages
- 181-192
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3045039
- OpenAlex
- W2051489981
- Cited by
- 833
- References
- 42
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 26 · 2023: 51 · 2022: 42 · 2021: 44 · 2020: 57 · 2019: 60 · 2018: 57 · 2017: 57 · 2016: 60 · 2015: 61 · 2014: 68 · 2013: 86 · 2012: 71
- FWCI
- 57.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- Funders
- National Institute on Aging (P01AG025204, RF1AG025516, P50AG005133, R37AG025516)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- amyloid-beta deposition, Alzheimer's disease, mild cognitive impairment, Pittsburgh compound B PET, APOE ε4, cognitive decline, disease progression, aging
- MeSH terms
- Aged, Aging, Alzheimer Disease, Aniline Compounds, Brain, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Polymorphism, Genetic, Severity of Illness Index, Thiazoles, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
